A Phase 3 interventional study of Levetiracetam in Partial Seizures, sponsored by UCB Japan Co. Ltd.. Completed at 21 sites in Japan. Open to participants aged 1 Month to 3 Years. Per ClinicalTrials.gov, last updated 2024-07-23.
Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing levetiracetam in Seizures — 9 open to participants now, 9 under way, 5 of them phase 3. Levetiracetam · Seizures.
Among the 52 studies testing levetiracetam in Seizures, this one is the 35th largest by enrollment, is one of 3 that started in 2017, is one of 19 in phase 3, and was the 40th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →9 of the 52 studies testing levetiracetam in Seizures are open now, in 6 countries. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Ayal A. Aizer, MD · Sites in United States
Ages 18+
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
All India Institute of Medical Sciences, Jodhpur · Sites in India
Ages 18–70
Ministry of Health and Sports, Myanmar · Sites in Burma
Ages 1 mo–12 yrs
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 1 Month to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 20 · Phase 4 11
First in 2000; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 68 across the 52 interventional studies. Of the 37 that completed or were terminated, 22 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 52 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Japan Co. Ltd., one of the names counted as UCB S.A.. Under that name alone:
UCB Japan Co. Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.
40 studies in Seizures by UCB S.A.: 3 open now, 4 under way, 4 of them phase 3. Of 36 finished, 31 (86%) have results posted.
Among the 40 studies in Seizures by UCB S.A., this one is the 31st largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2017, is one of 25 in phase 3, and was the 33rd registered.
UCB S.A.’s Seizures studies by the year they started, since 2000.
2 of the studies testing levetiracetam in Seizures that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT07072624All India Institute of Medical Sciences, JodhpurEarly Post-Traumatic Seizures Prevention Trial (E-PTS Trial) | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies testing levetiracetam in Seizures, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 40 in Seizures:
This tab as a report to print or save as PDF → With an account.
This is a study to confirm the efficacy of levetiracetam as adjunctive treatment or as monotherapy in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.
The study will consist of 2 periods. The First Period (6 weeks drug treatment) is designed to confirm efficacy of levetiracetam (LEV), and the Second Period is designed to evaluate the long-term efficacy and safety of LEV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects aged 1 month to \<6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to \<6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to \<4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day. At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to \<6 months or by LEV 20 mg/kg/day for subjects aged 6 months to \<4 years at 2-week intervals to 0 mg/kg/day.
Drug: Levetiracetam
levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
Also known as: Keppra, E-Keppra, LEV
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6
The percent difference in partial seizure frequency per week at Baseline and Study Visit 6 (Week 6) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 6)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 4
The percent difference in partial seizure frequency per week at Baseline and Study Visit 4 (Week 2) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 4)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
Time frame: From Baseline (Week 0) to Visit 4 (up to Week 2)
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 5
The percent difference in partial seizure frequency per week at Baseline and Study Visit 5 (Week 4) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 5)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
Time frame: From Baseline (Week 0) to Visit 5 (up to Week 4)
Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy
Percent difference in partial seizure frequency (PSF) per week at each Analysis Visit: {\[(Number of partial seizures per week at Baseline \[BL\]) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Positive value indicates reduction in PSF from BL. End of study (EOS)/early discontinuation visit (EDV) was based on last EDV and calculation of number of partial seizure per week were based on the period from the previous EDV visit. The mapping of seizure data to Analysis Visits was based on target dates of the visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to the next Analysis Visit (n+1). Data for one participant assessed within study duration was mapped to Analysis Visit 35/Week 300 based on statistical plan.
Time frame: From Baseline (Week 0), Week 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV (up to Week 295), and Safety follow-up (up to Week 295)
Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy
Percent difference in PSF per week on adjunctive therapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PSF per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. Positive value in percent difference from Baseline indicates reduction in PSF from Baseline. The mapping of seizure data to Analysis Visits was based on target dates of visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to next Analysis Visit (n+1).
Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV Week 2, EOS/EDV Week 4, and Safety follow-up (up to Week 295)
Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy
The percent difference in partial seizure frequency per week on monotherapy at Baseline and each analysis visit was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at analysis visit X)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. The maximum duration of study participation in monotherapy participants was shorter than in adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.
Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295)
Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy
Percent difference in PSF per week on monotherapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PFS per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. Maximum duration of study participation in monotherapy participants was shorter than adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.
Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation Participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The treatment-emergent adverse events (TEAEs) were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period
A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)
Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.
Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)
Percentage of Participants With TEAEs During the Combined First and Second Period
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period
A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.
Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
The study started to enroll participants in November 2017 and concluded in July 2023.
| Milestone | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| Started | 32 | 6 |
| Completed | 27 | 6 |
| Not completed | 5 | 0 |
| Withdrew: Adverse event, non-fatal | 2 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Milestone | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| Started | 27 | 6 |
| Completed | 8 | 4 |
| Not completed | 19 | 2 |
| Withdrew: Adverse event, non-fatal | 1 | 1 |
| Withdrew: Lack of efficacy | 11 | 0 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Approved drug available for indication | 1 | 0 |
| Withdrew: Protocol-specified withdrawal criterion met | 1 | 0 |
The percent difference in partial seizure frequency per week at Baseline and Study Visit 6 (Week 6) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 6)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
| percent change | Levetiracetam: Adjunctive Therapy |
|---|---|
| Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6 | 24.24 (-25.48 to 51.85) |
The percent difference in partial seizure frequency per week at Baseline and Study Visit 4 (Week 2) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 4)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
| percent change | Levetiracetam: Adjunctive Therapy |
|---|---|
| Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 4 | 8.62 (-343.1 to 100.0) |
The percent difference in partial seizure frequency per week at Baseline and Study Visit 5 (Week 4) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 5)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
| percent change | Levetiracetam: Adjunctive Therapy |
|---|---|
| Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 5 | 16.79 (-414.3 to 100.0) |
Percent difference in partial seizure frequency (PSF) per week at each Analysis Visit: {\[(Number of partial seizures per week at Baseline \[BL\]) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Positive value indicates reduction in PSF from BL. End of study (EOS)/early discontinuation visit (EDV) was based on last EDV and calculation of number of partial seizure per week were based on the period from the previous EDV visit. The mapping of seizure data to Analysis Visits was based on target dates of the visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to the next Analysis Visit (n+1). Data for one participant assessed within study duration was mapped to Analysis Visit 35/Week 300 based on statistical plan.
| percent change | Levetiracetam: Adjunctive Therapy |
|---|---|
| Week 8 | 35.53 (-137.9 to 100.0) |
| Week 10 | 59.39 (-138.2 to 100.0) |
| Week 12 | 50.90 (-167.8 to 100.0) |
| Week 15 | 60.29 (-129.4 to 100.0) |
| Week 18 | 82.74 (-22.3 to 100.0) |
| Week 21 | 80.33 (-44.1 to 100.0) |
| Week 24 | 88.44 (-97.8 to 100.0) |
| Week 27 | 93.84 (-4.8 to 100.0) |
| Week 30 | 98.05 (-4.8 to 100.0) |
| Week 36 | 100.00 (-94.5 to 100.0) |
| Week 48 | 98.70 (-28.4 to 100.0) |
| Week 60 | 100.00 (44.7 to 100.0) |
| Week 72 | 100.00 (32.0 to 100.0) |
| Week 84 | 100.00 (62.9 to 100.0) |
| Week 96 | 99.57 (78.2 to 100.0) |
| Week 108 | 100.00 (-48.0 to 100.0) |
| Week 120 | 100.00 (80.4 to 100.0) |
| Week 132 | 100.00 (50.7 to 100.0) |
| Week 144 | 100.00 (93.4 to 100.0) |
| Week 156 | 99.76 (93.5 to 100.0) |
| Week 168 | 99.74 (90.7 to 100.0) |
| Week 180 | 99.02 (86.1 to 100.0) |
| Week 192 | 99.76 (85.5 to 100.0) |
| Week 204 | 97.94 (78.3 to 100.0) |
| Week 216 | 96.58 (81.4 to 100.0) |
| Week 228 | 97.12 (96.6 to 100.0) |
| Week 240 | 96.36 (86.8 to 100.0) |
| Week 252 | 91.12 (85.3 to 96.9) |
| Week 264 | 96.91 (95.8 to 98.0) |
| Week 276 | 96.40 (95.2 to 97.6) |
| Week 288 | 96.14 (94.2 to 98.0) |
| Week 300 | 89.7 (89.7 to 89.7) |
| EOS/EDV | 21.86 (-120.1 to 100.0) |
| Safety Follow Up | 39.82 (-267.8 to 100.0) |
Percent difference in PSF per week on adjunctive therapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PSF per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. Positive value in percent difference from Baseline indicates reduction in PSF from Baseline. The mapping of seizure data to Analysis Visits was based on target dates of visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to next Analysis Visit (n+1).
| percentage of participants | Levetiracetam: Adjunctive Therapy |
|---|---|
| Week 2: <0% | 43.8 |
| Week 2: 0% - <25% | 18.8 |
| Week 2: 25% - <50% | 9.4 |
| Week 2: ≥ 50% | 28.1 |
| Week 2: ≥ 75% | 12.5 |
| Week 2: 100% | 9.4 |
| Week 4: <0% | 37.5 |
| Week 4: 0% - <25% | 18.8 |
| Week 4: 25% - <50% | 15.6 |
| Week 4: ≥ 50% | 28.1 |
| Week 4: ≥ 75% | 18.8 |
| Week 4: 100% | 9.4 |
| Week 6: <0% | 31.3 |
| Week 6: 0% - <25% | 15.6 |
| Week 6: 25% - <50% | 12.5 |
| Week 6: ≥ 50% | 28.1 |
| Week 6: ≥ 75% | 18.8 |
| Week 6: 100% | 15.6 |
| Week 8: <0% | 21.4 |
| Week 8: 0% - <25% | 14.3 |
| Week 8: 25% - <50% | 17.9 |
| Week 8: ≥ 50% | 35.7 |
| Week 8: ≥ 75% | 25.0 |
| Week 8: 100% | 17.9 |
| Week 10: <0% | 24.0 |
| Week 10: 0% - <25% | 12.0 |
| Week 10: 25% - <50% | 8.0 |
| Week 10: ≥ 50% | 52.0 |
| Week 10: ≥ 75% | 28.0 |
| Week 10: 100% | 20.0 |
| Week 12: <0% | 20.8 |
| Week 12: 0% - <25% | 4.2 |
| Week 12: 25% - <50% | 20.8 |
| Week 12: ≥ 50% | 45.8 |
| Week 12: ≥ 75% | 37.5 |
| Week 12: 100% | 25.0 |
| Week 15: <0% | 13.6 |
| Week 15: 0% - <25% | 9.1 |
| Week 15: 25% - <50% | 13.6 |
| Week 15: ≥ 50% | 63.6 |
| Week 15: ≥ 75% | 36.4 |
| Week 15: 100% | 27.3 |
| Week 18: <0% | 9.1 |
| Week 18: 0% - <25% | 4.5 |
| Week 18: 25% - <50% | 9.1 |
| Week 18: ≥ 50% | 68.2 |
| Week 18: ≥ 75% | 54.5 |
| Week 18: 100% | 31.8 |
| Week 21: <0% | 10.0 |
| Week 21: 0% - <25% | 5.0 |
| Week 21: 25% - <50% | 5.0 |
| Week 21: ≥ 50% | 80.0 |
| Week 21: ≥ 75% | 55.0 |
| Week 21: 100% | 30.0 |
| Week 24: <0% | 10.0 |
| Week 24: 0% - <25% | 10.0 |
| Week 24: 25% - <50% | 5.0 |
| Week 24: ≥ 50% | 70.0 |
| Week 24: ≥ 75% | 55.0 |
| Week 24: 100% | 40.0 |
| Week 27: <0% | 5.3 |
| Week 27: 0% - <25% | 5.3 |
| Week 27: 25% - <50% | 10.5 |
| Week 27: ≥ 50% | 73.7 |
| Week 27: ≥ 75% | 52.6 |
| Week 27: 100% | 36.8 |
| Week 30: <0% | 5.6 |
| Week 30: 0% - <25% | 11.1 |
| Week 30: 25% - <50% | 5.6 |
| Week 30: ≥ 50% | 72.2 |
| Week 30: ≥ 75% | 55.6 |
| Week 30: 100% | 44.4 |
| Week 36: <0% | 11.8 |
| Week 36: 0% - <25% | 5.9 |
| Week 36: 25% - <50% | 0 |
| Week 36: ≥ 50% | 76.5 |
| Week 36: ≥ 75% | 70.6 |
| Week 36: 100% | 52.9 |
| Week 48: <0% | 6.3 |
| Week 48: 0% - <25% | 12.5 |
| Week 48: 25% - <50% | 6.3 |
| Week 48: ≥ 50% | 75.0 |
| Week 48: ≥ 75% | 75.0 |
| Week 48:100% | 43.8 |
| Week 60: <0% | 0 |
| Week 60: 0% - <25% | 0 |
| Week 60: 25% - <50% | 6.3 |
| Week 60: ≥ 50% | 75.0 |
| Week 60: ≥ 75% | 68.8 |
| Week 60: 100% | 43.8 |
| Week 72: <0% | 0 |
| Week 72: 0% - <25% | 0 |
| Week 72: 25% - <50% | 7.7 |
| Week 72: ≥ 50% | 92.3 |
| Week 72: ≥ 75% | 76.9 |
| Week 72: 100% | 53.8 |
| Week 84: <0% | 0 |
| Week 84: 0% - <25% | 0 |
| Week 84: 25% - <50% | 0 |
| Week 84: ≥ 50% | 100 |
| Week 84: ≥ 75% | 84.6 |
| Week 84: 100% | 53.8 |
| Week 96: <0% | 0 |
| Week 96: 0% - <25% | 0 |
| Week 96: 25% - <50% | 0 |
| Week 96: ≥ 50% | 92.3 |
| Week 96: ≥ 75% | 92.3 |
| Week 96: 100% | 46.2 |
| Week 108: <0% | 8.3 |
| Week 108: 0% - <25% | 0 |
| Week 108: 25% - <50% | 0 |
| Week 108: ≥ 50% | 83.3 |
| Week 108: ≥ 75% | 75.0 |
| Week 108: 100% | 50.0 |
| Week 120: <0% | 0 |
| Week 120: 0% - <25% | 0 |
| Week 120: 25% - <50% | 0 |
| Week 120: ≥ 50% | 90.9 |
| Week 120: ≥ 75% | 90.9 |
| Week 120: 100% | 63.6 |
| Week 132: <0% | 0 |
| Week 132: 0% - <25% | 0 |
| Week 132: 25% - <50% | 0 |
| Week 132: ≥ 50% | 80.0 |
| Week 132: ≥ 75% | 70.0 |
| Week 132: 100% | 50.0 |
| Week 144: <0% | 0 |
| Week 144: 0% - <25% | 0 |
| Week 144: 25% - <50% | 0 |
| Week 144: ≥ 50% | 87.5 |
| Week 144: ≥ 75% | 87.5 |
| Week 144: 100% | 50.0 |
| Week 156: <0% | 0 |
| Week 156: 0% - <25% | 0 |
| Week 156: 25% - <50% | 0 |
| Week 156: ≥ 50% | 85.7 |
| Week 156: ≥ 75% | 85.7 |
| Week 156: 100% | 42.9 |
| Week 168: <0% | 0 |
| Week 168: 0% - <25% | 0 |
| Week 168: 25% - <50% | 0 |
| Week 168: ≥ 50% | 100 |
| Week 168: ≥ 75% | 100 |
| Week 168: 100% | 50.0 |
| Week 180: <0% | 0 |
| Week 180: 0% - <25% | 0 |
| Week 180: 25% - <50% | 0 |
| Week 180: ≥ 50% | 100 |
| Week 180: ≥ 75% | 100 |
| Week 180: 100% | 50.0 |
| Week 192: <0% | 0 |
| Week 192: 0% - <25% | 0 |
| Week 192: 25% - <50% | 0 |
| Week 192: ≥ 50% | 100 |
| Week 192: ≥ 75% | 100 |
| Week 192: 100% | 50.0 |
| Week 204: <0% | 0 |
| Week 204: 0% - <25% | 0 |
| Week 204: 25% - <50% | 0 |
| Week 204: ≥ 50% | 83.3 |
| Week 204: ≥ 75% | 83.3 |
| Week 204: 100% | 16.7 |
| Week 216: <0% | 0 |
| Week 216: 0% - <25% | 0 |
| Week 216: 25% - <50% | 0 |
| Week 216: ≥ 50% | 100 |
| Week 216: ≥ 75% | 100 |
| Week 216: 100% | 20.0 |
| Week 228: <0% | 0 |
| Week 228: 0% - <25% | 0 |
| Week 228: 25% - <50% | 0 |
| Week 228: ≥ 50% | 60.0 |
| Week 228: ≥ 75% | 60.0 |
| Week 228: 100% | 20.0 |
| Week 240: <0% | 0 |
| Week 240: 0% - <25% | 0 |
| Week 240: 25% - <50% | 0 |
| Week 240: ≥ 50% | 100 |
| Week 240: ≥ 75% | 100 |
| Week 240: 100% | 33.3 |
| Week 252: <0% | 0 |
| Week 252: 0% - <25% | 0 |
| Week 252: 25% - <50% | 0 |
| Week 252: ≥ 50% | 66.7 |
| Week 252: ≥ 75% | 66.7 |
| Week 252: 100% | 0 |
| Week 264: <0% | 0 |
| Week 264: 0% - <25% | 0 |
| Week 264: 25% - <50% | 0 |
| Week 264: ≥ 50% | 100 |
| Week 264: ≥ 75% | 100 |
| Week 264: 100% | 0 |
| Week 276: <0% | 0 |
| Week 276: 0% - <25% | 0 |
| Week 276: 25% - <50% | 0 |
| Week 276: ≥ 50% | 100 |
| Week 276: ≥ 75% | 100 |
| Week 276: 100% | 0 |
| Week 288: <0% | 0 |
| Week 288: 0% - <25% | 0 |
| Week 288: 25% - <50% | 0 |
| Week 288: ≥ 50% | 100 |
| Week 288: ≥ 75% | 100 |
| Week 288: 100% | 0 |
| Week 300: <0% | 0 |
| Week 300: 0% - <25% | 0 |
| Week 300: 25% - <50% | 0 |
| Week 300: ≥ 50% | 50.0 |
| Week 300: ≥ 75% | 50.0 |
| Week 300: 100% | 0 |
| EOS/EDV, Week 2: <0% | 3.1 |
| EOS/EDV, Week 2: 0% - <25% | 3.1 |
| EOS/EDV, Week 2: 25% - <50% | 0 |
| EOS/EDV, Week 2: ≥ 50% | 3.1 |
| EOS/EDV, Week 2: ≥ 75% | 3.1 |
| EOS/EDV, Week 2: 100% | 3.1 |
| EOS/EDV, Week 4: <0% | 20.0 |
| EOS/EDV, Week 4: 0% - <25% | 10.0 |
| EOS/EDV, Week 4: 25% - <50% | 20.0 |
| EOS/EDV, Week 4: ≥ 50% | 20.0 |
| EOS/EDV, Week 4: ≥ 75% | 10.0 |
| EOS/EDV, Week 4: 100% | 0 |
| Safety Follow Up: <0% | 37.5 |
| Safety Follow Up: 0% - <25% | 4.2 |
| Safety Follow Up: 25% - <50% | 12.5 |
| Safety Follow Up: ≥ 50% | 45.8 |
| Safety Follow Up: ≥ 75% | 29.2 |
| Safety Follow Up: 100% | 20.8 |
The percent difference in partial seizure frequency per week on monotherapy at Baseline and each analysis visit was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at analysis visit X)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. The maximum duration of study participation in monotherapy participants was shorter than in adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.
| percent change | Levetiracetam: Monotherapy |
|---|---|
| Week 2 | -51.87 (-731.6 to 100.0) |
| Week 4 | 4.88 (-115.9 to 100.0) |
| Week 6 | 51.10 (-325.0 to 100.0) |
| Week 8 | 100.00 (-1.1 to 100.0) |
| Week 10 | 100.00 (-277.1 to 100.0) |
| Week 12 | 76.92 (-10.0 to 100.0) |
| Week 15 | 100.00 (-78.1 to 100.0) |
| Week 18 | 91.58 (58.1 to 100.0) |
| Week 21 | 100.00 (76.9 to 100.0) |
| Week 24 | 100.00 (92.3 to 100.0) |
| Week 27 | 100.00 (26.7 to 100.0) |
| Week 30 | 100.00 (37.1 to 100.0) |
| Week 36 | 100.00 (16.2 to 100.0) |
| Week 48 | 98.08 (-138.3 to 100.0) |
| Week 60 | 94.23 (-41.4 to 100.0) |
| Week 72 | 92.31 (-36.2 to 100.0) |
| Week 84 | 95.79 (-86.0 to 100.0) |
| Week 96 | 98.08 (-65.0 to 100.0) |
| Week 108 | 96.15 (-44.0 to 100.0) |
| Week 120 | 93.68 (-46.7 to 100.0) |
| Week 132 | 92.63 (-138.3 to 100.0) |
| Week 144 | 92.63 (-106.9 to 100.0) |
| Week 156 | 94.73 (8.3 to 100.0) |
| Week 168 | 100.00 (-70.2 to 100.0) |
| Week 180 | 100.00 (-274.5 to 100.0) |
| Week 192 | 100.00 (-223.0 to 100.0) |
| Week 204 | 100.00 (100.0 to 100.0) |
| Week 216 | 100.00 (100.0 to 100.0) |
| Week 228 | 100.00 (100.0 to 100.0) |
| Week 240 | 100.00 (100.00 to 100.00) |
| Week 252 | 100.00 (100.00 to 100.00) |
| Week 264 | 100.00 (100.00 to 100.00) |
| Week 276 | 100.00 (100.00 to 100.00) |
| Safety Follow Up | 100.0 (100.0 to 100.0) |
Percent difference in PSF per week on monotherapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PFS per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. Maximum duration of study participation in monotherapy participants was shorter than adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.
| percentage of participants | Levetiracetam: Monotherapy |
|---|---|
| Week 2: <0% | 60.0 |
| Week 2: 0% - <25% | 0 |
| Week 2: 25% - <50% | 20.0 |
| Week 2: ≥ 50% | 40.0 |
| Week 2: ≥ 75% | 20.0 |
| Week 2: 100% | 20.0 |
| Week 4: <0% | 50.0 |
| Week 4: 0% - <25% | 0 |
| Week 4: 25% - <50% | 16.7 |
| Week 4: ≥ 50% | 33.3 |
| Week 4: ≥ 75% | 33.3 |
| Week 4: 100% | 33.3 |
| Week 6: <0% | 33.3 |
| Week 6: 0% - <25% | 0 |
| Week 6: 25% - <50% | 16.7 |
| Week 6: ≥ 50% | 50.0 |
| Week 6: ≥ 75% | 33.3 |
| Week 6: 100% | 16.7 |
| Week 8: <0% | 16.7 |
| Week 8: 0% - <25% | 16.7 |
| Week 8: 25% - <50% | 0 |
| Week 8: ≥ 50% | 50.0 |
| Week 8: ≥ 75% | 50.0 |
| Week 8: 100% | 50.0 |
| Week 10: <0% | 20.0 |
| Week 10: 0% - <25% | 0 |
| Week 10: 25% - <50% | 0 |
| Week 10: ≥ 50% | 80.0 |
| Week 10: ≥ 75% | 80.0 |
| Week 10: 100% | 60.0 |
| Week 12: <0% | 20.0 |
| Week 12: 0% - <25% | 0 |
| Week 12: 25% - <50% | 20.0 |
| Week 12: ≥ 50% | 60.0 |
| Week 12: ≥ 75% | 60.0 |
| Week 12: 100% | 40.0 |
| Week 15: <0% | 20.0 |
| Week 15: 0% - <25% | 0 |
| Week 15: 25% - <50% | 20.0 |
| Week 15: ≥ 50% | 60.0 |
| Week 15: ≥ 75% | 60.0 |
| Week 15: 100% | 60.0 |
| Week 18: <0% | 0 |
| Week 18: 0% - <25% | 0 |
| Week 18: 25% - <50% | 0 |
| Week 18: ≥ 50% | 100 |
| Week 18: ≥ 75% | 80.0 |
| Week 18: 100% | 40.0 |
| Week 21: <0% | 0 |
| Week 21: 0% - <25% | 0 |
| Week 21: 25% - <50% | 0 |
| Week 21: ≥ 50% | 100 |
| Week 21: ≥ 75% | 100 |
| Week 21: 100% | 60.0 |
| Week 24: <0% | 0 |
| Week 24: 0% - <25% | 0 |
| Week 24: 25% - <50% | 0 |
| Week 24: ≥ 50% | 100 |
| Week 24: ≥ 75% | 100 |
| Week 24: 100% | 80.0 |
| Week 27: <0% | 0 |
| Week 27: 0% - <25% | 0 |
| Week 27: 25% - <50% | 20.0 |
| Week 27: ≥ 50% | 80.0 |
| Week 27: ≥ 75% | 80.0 |
| Week 27: 100% | 80.0 |
| Week 30: <0% | 0 |
| Week 30: 0% - <25% | 0 |
| Week 30: 25% - <50% | 20.0 |
| Week 30: ≥ 50% | 80.0 |
| Week 30: ≥ 75% | 60.0 |
| Week 30: 100% | 60.0 |
| Week 36: <0% | 0 |
| Week 36: 0% - <25% | 20.0 |
| Week 36: 25% - <50% | 0 |
| Week 36: ≥ 50% | 80.0 |
| Week 36: ≥ 75% | 80.0 |
| Week 36: 100% | 60.0 |
| Week 48: <0% | 20.0 |
| Week 48: 0% - <25% | 0 |
| Week 48: 25% - <50% | 0 |
| Week 48: ≥ 50% | 80.0 |
| Week 48: ≥ 75% | 80.0 |
| Week 48:100% | 40.0 |
| Week 60: <0% | 20.0 |
| Week 60: 0% - <25% | 0 |
| Week 60: 25% - <50% | 0 |
| Week 60: ≥ 50% | 80.0 |
| Week 60: ≥ 75% | 80.0 |
| Week 60: 100% | 40.0 |
| Week 72: <0% | 20.0 |
| Week 72: 0% - <25% | 0 |
| Week 72: 25% - <50% | 0 |
| Week 72: ≥ 50% | 80.0 |
| Week 72: ≥ 75% | 80.0 |
| Week 72: 100% | 40.0 |
| Week 84: <0% | 20.0 |
| Week 84: 0% - <25% | 0 |
| Week 84: 25% - <50% | 0 |
| Week 84: ≥ 50% | 80.0 |
| Week 84: ≥ 75% | 80.0 |
| Week 84: 100% | 40.0 |
| Week 96: <0% | 20.0 |
| Week 96: 0% - <25% | 0 |
| Week 96: 25% - <50% | 0 |
| Week 96: ≥ 50% | 80.0 |
| Week 96: ≥ 75% | 80.0 |
| Week 96: 100% | 40.0 |
| Week 108: <0% | 20.0 |
| Week 108: 0% - <25% | 0 |
| Week 108: 25% - <50% | 0 |
| Week 108: ≥ 50% | 80.0 |
| Week 108: ≥ 75% | 80.0 |
| Week 108: 100% | 40.0 |
| Week 120: <0% | 20.0 |
| Week 120: 0% - <25% | 0 |
| Week 120: 25% - <50% | 0 |
| Week 120: ≥ 50% | 80.0 |
| Week 120: ≥ 75% | 80.0 |
| Week 120: 100% | 40.0 |
| Week 132: <0% | 20.0 |
| Week 132: 0% - <25% | 0 |
| Week 132: 25% - <50% | 0 |
| Week 132: ≥ 50% | 60.0 |
| Week 132: ≥ 75% | 60.0 |
| Week 132: 100% | 40.0 |
| Week 144: <0% | 25.0 |
| Week 144: 0% - <25% | 0 |
| Week 144: 25% - <50% | 0 |
| Week 144: ≥ 50% | 75.0 |
| Week 144: ≥ 75% | 75.0 |
| Week 144: 100% | 50.0 |
| Week 156: <0% | 0 |
| Week 156: 0% - <25% | 25.0 |
| Week 156: 25% - <50% | 0 |
| Week 156: ≥ 50% | 75.0 |
| Week 156: ≥ 75% | 75.0 |
| Week 156: 100% | 50.0 |
| Week 168: <0% | 25.0 |
| Week 168: 0% - <25% | 0 |
| Week 168: 25% - <50% | 0 |
| Week 168: ≥ 50% | 75.0 |
| Week 168: ≥ 75% | 75.0 |
| Week 168: 100% | 75.0 |
| Week 180: <0% | 25.0 |
| Week 180: 0% - <25% | 0 |
| Week 180: 25% - <50% | 0 |
| Week 180: ≥ 50% | 50.0 |
| Week 180: ≥ 75% | 50.0 |
| Week 180: 100% | 50.0 |
| Week 192: <0% | 33.3 |
| Week 192: 0% - <25% | 0 |
| Week 192: 25% - <50% | 0 |
| Week 192: ≥ 50% | 66.7 |
| Week 192: ≥ 75% | 66.7 |
| Week 192: 100% | 66.7 |
| Week 204: <0% | 0 |
| Week 204: 0% - <25% | 0 |
| Week 204: 25% - <50% | 0 |
| Week 204: ≥ 50% | 66.7 |
| Week 204: ≥ 75% | 66.7 |
| Week 204: 100% | 66.7 |
| Week 216: <0% | 0 |
| Week 216: 0% - <25% | 0 |
| Week 216: 25% - <50% | 0 |
| Week 216: ≥ 50% | 100 |
| Week 216: ≥ 75% | 100 |
| Week 216: 100% | 100 |
| Week 228: <0% | 0 |
| Week 228: 0% - <25% | 0 |
| Week 228: 25% - <50% | 0 |
| Week 228: ≥ 50% | 50.0 |
| Week 228: ≥ 75% | 50.0 |
| Week 228: 100% | 50.0 |
| Week 240: <0% | 0 |
| Week 240: 0% - <25% | 0 |
| Week 240: 25% - <50% | 0 |
| Week 240: ≥ 50% | 100 |
| Week 240: ≥ 75% | 100 |
| Week 240: 100% | 100 |
| Week 252: <0% | 0 |
| Week 252: 0% - <25% | 0 |
| Week 252: 25% - <50% | 0 |
| Week 252: ≥ 50% | 100 |
| Week 252: ≥ 75% | 100 |
| Week 252: 100% | 100 |
| Week 264: <0% | 0 |
| Week 264: 0% - <25% | 0 |
| Week 264: 25% - <50% | 0 |
| Week 264: ≥ 50% | 100 |
| Week 264: ≥ 75% | 100 |
| Week 264: 100% | 100 |
| Week 276: <0% | 0 |
| Week 276: 0% - <25% | 0 |
| Week 276: 25% - <50% | 0 |
| Week 276: ≥ 50% | 100 |
| Week 276: ≥ 75% | 100 |
| Week 276: 100% | 100 |
| Safety Follow Up: <0% | 0 |
| Safety Follow Up: 0% - <25% | 0 |
| Safety Follow Up: 25% - <50% | 0 |
| Safety Follow Up: ≥ 50% | 100 |
| Safety Follow Up: ≥ 75% | 100 |
| Safety Follow Up: 100% | 100 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation Participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The treatment-emergent adverse events (TEAEs) were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
| percentage of participants | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period | 62.5 | 0 |
A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
| percentage of participants | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period | 9.4 | 0 |
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.
| percentage of participants | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period | 6.3 | 0 |
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
| percentage of participants | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| Percentage of Participants With TEAEs During the Combined First and Second Period | 96.9 | 100 |
A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
| percentage of participants | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period | 56.3 | 33.3 |
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.
| percentage of participants | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period | 9.4 | 16.7 |
Collected over From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam: Adjunctive Therapy | 0/32 (0%) | 18/32 (56.3%) | 28/32 (87.5%) |
| Levetiracetam: Monotherapy | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| GastroenteritisInfections and infestations | 1/32 | 1/6 |
| EpilepsyNervous system disorders | 2/32 | 1/6 |
| Seizure clusterNervous system disorders | 2/32 | 1/6 |
| PyrexiaGeneral disorders | 0/32 | 1/6 |
| InfluenzaInfections and infestations | 0/32 | 1/6 |
| Pneumonia bacterialInfections and infestations | 0/32 | 1/6 |
| Pneumonia viralInfections and infestations | 3/32 | 0/6 |
| Status epilepticusNervous system disorders | 3/32 | 0/6 |
| Infantile spasmsNervous system disorders | 3/32 | 0/6 |
| BronchitisInfections and infestations | 2/32 | 0/6 |
| Event | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy |
|---|---|---|
| NasopharyngitisInfections and infestations | 17/32 | 5/6 |
| Hand-foot-and-mouth diseaseInfections and infestations | 3/32 | 3/6 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/32 | 3/6 |
| PyrexiaGeneral disorders | 12/32 | 2/6 |
| Conjunctivitis allergicEye disorders | 3/32 | 2/6 |
| GastroenteritisInfections and infestations | 7/32 | 2/6 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 3/32 | 2/6 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 3/32 | 2/6 |
| EczemaSkin and subcutaneous tissue disorders | 9/32 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 8/32 | 0/6 |
Baseline Characteristics refer to the SS_A and SS_M. The SS_A consisted of all enrolled participants on adjunctive therapy who received at least 1 dose of study medication in the evaluation period. The SS_M consisted of all enrolled participants on monotherapy who received at least 1 dose of study medication in the evaluation period.
| Age, Continuous(Years) | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy | Total |
|---|---|---|---|
| Mean | 14.7 ± 10.7 | 32.4 ± 13.2 | 17.5 ± 12.7 |
| Age, Customized(Participants) | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy | Total |
|---|---|---|---|
| 28 days - <24 months | 26 | 3 | 29 |
| 24 months - <12 years | 6 | 3 | 9 |
| Sex: Female, Male(Participants) | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy | Total |
|---|---|---|---|
| Female | 15 | 5 | 20 |
| Male | 17 | 1 | 18 |
| Race/Ethnicity, Customized(Participants) | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy | Total |
|---|---|---|---|
| Asian | 32 | 6 | 38 |
| Race/Ethnicity, Customized(Participants) | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy | Total |
|---|---|---|---|
| Japan | 32 | 6 | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Nov 2017 to primary completion in Jun 2021, 42 months.
Results were first posted in Jul 2024, 3 years 1 month after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's 42 months is below that.
Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam